Compare Biogen Inc (BIIB) vs Vertiv Holdings Co (VRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Vertiv Holdings Co — how do they compare? Biogen Inc trades at $190.68 (market cap $28.34B), while Vertiv Holdings Co trades at $301.1 (market cap $116.61B). The key difference: Vertiv Holdings Co is far larger — about 4.1× Biogen Inc's market cap, and Vertiv Holdings Co pays a 0.08% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | VRT | |
|---|---|---|
Market Cap | $28.34B | $116.61B |
Sector | Health | Technology |
52-Week High | $216.63 | $376.23 |
52-Week Low | $122.68 | $121.82 |
Enterprise Value | $30.62B | $117.37B |
Dividend Yield | — | 0.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Vertiv Holdings (VRT) trades at $305.87, down 4.07% today, amid strong fundamental performance with consistent earnings beats and robust AI-driven demand. The stock shows neutral technical signals with support at $300 and resistance at $314, while maintaining impressive profitability metrics including 45.1% ROE and 14.37% net margin. Recent news highlights Vertiv's $15 billion order backlog and expansion in Malaysia to capitalize on AI infrastructure growth.
The outlook remains positive with 94.7% analyst buy ratings and a $407.45 consensus target, representing 33% upside potential. Key risks include premium valuation multiples (P/E 76.28) and competitive pressures, but strong cash flow generation and AI infrastructure tailwinds support continued growth momentum through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Vertiv Holdings Co
Vertiv is a global leader in critical digital infrastructure, providing essential power, cooling, and IT management solutions for data centers, communication networks, and industrial facilities. As the primary provider of advanced thermal management and liquid cooling systems, Vertiv is a central player in the AI revolution, enabling the extreme density and power requirements of next-generation GPU-driven computing.
Read more on VRT →
